Article
Targeting LINC00152 activates cAMP/Ca <sup>2+</sup> /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer
2023-11-05
Abstract excerpt
Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER+) breast cancer, constituting around 75% of all cases. However, emergence of resistance is common, necessitating the identification of novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen resistance via blocking tamoxifen-induced ferroptosis, an iro...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 33fc0934-d0e1-52db-887e-defac624c83a
- DOI
- 10.1101/2023.11.05.565697
